Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 19 2025
0mins
Source: Globenewswire
Research Findings: A study indicates that combining EEG/ERP and vMRI significantly improves the accuracy of diagnosing subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia, achieving up to 87% accuracy when both methods are used together.
Company Advancements: Firefly Neuroscience is leveraging its recent acquisition of Evoke Neuroscience to enhance its AI-driven Brain Network Analytics (BNA™) technology, aiming for earlier detection and intervention in Alzheimer's disease through accessible diagnostic tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
